



FOR IMMEDIATE RELEASE

CONTACT:

Caleb Liptak

(407) 722-7830

cliptak@findsomewinmore.com

Leading Digital Pill Solution Surpasses 10,000 Ingestions

etectRx's ID-Cap™ System Expanding to New Treatment Areas

GAINESVILLE, Fla. (March 24, 2023) – etectRx™, Inc. (etectRx™), the standard in FDA-cleared digital medication adherence, today announced that its digital pill, the ID-Cap System has surpassed 10,000 ingestions, a significant milestone for the company with a reputation for demonstrating strong results and providing data to accurately track patients' adherence to their oral medications.

Patients using the ID-Cap System in multiple treatment areas recorded an aggregate 94 percent confirmed adherence rate through the first 10,000 ingestions. The technology is the only ingestible sensor solution that allows care teams to monitor, track, trend, report, and provide real-time, accurate data throughout the patient journey. When nonadherence is detected with the technology, care teams can intervene in a timely fashion to send real-time dosing reminders to patients' smartphone apps.

In addition to confirming high levels of adherence, the ID-Cap System revealed:

- 52% of patients exceeded 95% adherence.
- 15% of patients fell below 80% adherence.
- Clinicians were able to identify patients with missed doses on the same day as the dose was missed, and able to identify trends of nonadherence within days.
- Patient nonadherence was converted to adherence in 54% of cases where an intervention message was sent by the system.

etectRx gained FDA clearance for its innovative ID-Cap System technology in December 2019. Since FDA clearance, the technology has generated strong, accurate results across multiple indications, particularly with patient populations with traditionally poor levels of medication adherence, including those with substance abuse disorders.

"This milestone shines a bright light on the fact that the ID-Cap system consistently gets results," said Eric Buffkin, CEO of etectRx. "Our technology has been proven time and time again across varied patient populations and diverse treatment areas to reliably identify adherence immediately, allowing care teams to capture accurate data and intervene only when necessary to improve dosing regimens."

"The ID-Cap System has helped tremendously in the ongoing quest to understand and objectify situations in which people forget or neglect to take their medication," said Peter R. Chai, M.D., M.M.S. of Brigham and Women's Hospital. "As the technology continues to produce accurate, real-time data for care teams, we will be able to shift the paradigm from responding to nonadherence, to anticipating and mitigating it."



A seamless, end-to-end solution for remotely monitoring, tracking and improving medication therapy in real time, the ID-Cap System consists of a dashboard to provide researchers with insight into each participant's ingestion history and adherence, a smartphone app used by the participants to provide critical engagement and interventions, and novel ingestible sensors to automatically document each time patients take a dose of their medication.

###

About etectRx™

etectRx is a digital health company. The FDA-cleared ID-Cap System uniquely addresses the issue with adherence to (oral) medication. The accurate, flexible, and simple digital pill system allows researchers, pharmacists, physicians, and pharmaceutical companies to rethink approaches to medication adherence, innovate with confidence, and accelerate patient outcomes. To learn more, visit <https://etectrx.com/>.